Efficacy and safety of low-dose everolimus and tacrolimus in kidney transplant recipients: A retrospective study

Table 1 Demographic data and timing of everolimus switch and creatinine results

Patient ID	Age	Gender	Pre-transplant diabetes	Time from KT to switch (years)	Cr before switch (mg/dL)	Cr 1 month after (mg/dL)
KT-01	59	Male	Yes	2.5	1.13	1.22
KT-02	49	Male	No	2.3	1.30	1.18
KT-03	35	Male	No	2.8	1.27	0.98
KT-04	63	Male	Yes	1.9	0.78	1.21
KT-05	28	Female	No	1.2	1.59	1.17
KT-06	41	Male	No	2.4	1.57	1.76
KT-07	59	Male	Yes	2.5	1.45	1.02
KT-08	39	Male	Yes	2.1	1.34	1.98
KT-09	43	Female	Yes	2.5	0.80	1.07
KT-10	31	Male	Yes	0.8	1.26	1.25
KT-11	31	Female	Yes	2.0	1.29	1.70
KT-12	44	Male	Yes	1.9	1.08	0.90
KT-13	56	Male	No	1.1	1.38	1.47
KT-14	60	Male	Yes	1.2	1.64	1.89
KT-15	44	Female	Yes	1.1	2.32	0.75
KT-16	23	Female	No	2.3	1.53	1.45
KT-17	42	Male	Yes	1.6	1.57	1.48
KT-18	22	Male	No	2.0	1.42	1.68
KT-19	44	Male	Yes	2.8	0.60	0.90
KT-20	64	Male	No	1.5	1.44	0.87
KT-21	50	Male	No	1.8	1.48	1.58
KT-22	58	Female	Yes	2.5	2.58	1.50
KT-23	22	Male	Yes	1.5	1.36	1.48
KT-24	41	Male	No	1.2	1.59	1.52
KT-25	53	Male	No	1.6	1.43	1.11
KT-26	32	Female	No	1.3	0.91	1.47
KT-27	42	Male	No	2.9	1.98	1.49
KT-28	64	Female	Yes	2.6	1.80	1.10
KT-29	45	Female	Yes	0.8	1.81	2.11
KT-30	69	Male	Yes	2.7	1.03	1.56
KT-31	47	Male	No	2.6	2.10	0.92
KT-32	62	Female	No	1.4	0.81	1.64
KT-33	48	Male	Yes	2.8	1.72	1.40
KT-34	36	Male	Yes	2.1	2.46	1.69
KT-35	35	Male	Yes	2.6	0.99	2.03
KT-36	67	Male	Yes	2.8	1.19	1.06

KT: Kidney transplantation; Cr: Creatinine.